🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

entospharma is excited to announce a new partnership with a clinical-stage biopharma company to develop new therapeutics with our Fusogenix tech to target autoimmune and inflammatory diseases. bit.ly/Entos_2019 #pressreleases #immunotherapy #nextgeneration

Congrats to #UAlberta spinoff Entos on partnership w/ clinical stage biopharma to develop new autoimmune & inflammatory disease therapeutics using Entos’ Fusogenix technology. #immunotherapy #ABbiz @TECEdmonton @WD_Canada Alberta Jobs, Economy, Trade and Immigration University Hospital Foundation Innovate Edmonton

Great Alberta Impact “live” episode with our COO Catalina Vasquez Catalina and CCO Colin Coros Colin Coros! Watch to learn more about our Prostate Cancer diagnostic test. m.youtube.com/watch?v=LHQG2R…

We're at ASEMV2019 in Pacific Grove, CA and looking forward to meeting you at our CEO John Lewis' talk and our booth to chat about EVs, uFCM and diagnostics! nanosticsdx.com/events #extracellularvesicles #ASEMV2019

ASEMV2019 Display table open for business!

We're expanding our Nanostics Inc. ClarityDX Prostate clinical validation study into the US with a recruitment site at Century Clinical Research Inc., Daytona Beach, FL. Read more at bit.ly/Nanostics nanosticsdx.com #clinicaltrials #ProstateCancer

Going to the BIO Investor Forum company talks? CEO John Lewis is presenting on Oct 22. John and CCO Colin Coros look forward to chatting about our diagnostic platform and lead product ClarityDX Prostate. More at nanosticsdx.com/events #BIF19 #diagnostics #prostatecancer

The men of @Nanostics R&D; Mike Wong, Renjith Pillai and Desmond Pink @pinknewfie say, "Grow a Mo, save a Bro" and that's what they did. Go to nanosticsdx.com to find out about ClarityDX Prostate. #Movember #ProstateCancer

We're in San Francisco for #JPM20! Entos develops next-gen nucleic acid-therapies with our proprietary delivery system: Fusogenix. DM CEO John Lewis APCaRI and CSO Arun Raturi arun raturi to learn more! entospharma.com #biopharma #HealthTech #JPM2020

Add John Lewis' presentation on Nanostics and ClarityDX Prostate-highly accurate aggressive prostate cancer test- to your #JPM20 calendar! #biotechshowcase, Hilton Union Square, Monday, Jan 13, 4:45 pm. DM Catalina Catalina or Colin Colin Coros to meet! #diagnostics

CSO Desmond Pink @pinknewfie is in Miami, Florida this week to give a talk on Nanostics' liquid biopsy, ClarityDX Prostate at AACR's Advances in Liquid Biopsies. Must See! DM Desmond to chat on #EVs #Extracellularvesicles #flowcytometry #AACRLB20

Nanostics accepts the challenge! Our study Monitor/Data Manager, Aditya Muley, will be at this course too. Meet with Aditya to get your awesome UofA (size med) hoodie!

Catalina Vasquez and Colin Coros want to thank Joanne Fedeyko Joanne Fedeyko at @connectsv for this excellent opportunity to meet and have discussions with Silicon Valley entrepreneurs, VC, and inspirational coaches. #CanadianLandingPad #startup #SiliconValley

Entos’ COVID-19 vaccine Phase trial met 1st milestone-thank you Halifax! CCfV is now enrolling Halifax area adults to complete the trial. Interested? Learn more at bit.ly/trialvolunteer #COVID19Vaccines BioAlberta Dalhousie University @VACCres Global Public Affairs UAlberta Research & Innovation

Some great work being done on the ground in #Halifax to support clinical trials for Canadian domestic #COVID19 vaccines! 🇨🇦💉

Interested in volunteering? Please contact IWK! Details in CBC news below. #COVID19 Global Public Affairs Dalhousie University UAlberta Research & Innovation cbc.ca/news/canada/no…

We're excited to announce the launch of a clinical study to validate our bladder cancer diagnostic test and improve patient outcomes. Supported in part by Alberta Innovates AICE-Concepts. bwnews.pr/3ISH41g #diagnostics BioAlberta Health Innovation Hub at UAlberta Health Cities UAlberta Research & Innovation Chris Smith

Excited to announce receiving the CE Mark for its ClarityDX Prostate® test that uses machine-learning plus biological and clinical biomarker data to generate a risk score for clinically significant prostate cancer. prn.to/3dODeLb

Excited to announce Aubrey Rankin’s appointment to Nanostics’ Board of Directors! Read more at nanosticsdx.com/media/ or bit.ly/3X2T9rg #ProstateCancer #ClarityDXProstate #diagnosis